Messenger Ribonucleic Acid Quality Monitoring Market Report 2026

The messenger ribonucleic acid quality monitoring market size has grown rapidly in recent years. It will grow from $1.47 billion in 2025 to $1.64 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to expansion of mRNA research applications, early adoption of analytical validation tools, growth of academic and clinical research programs, rising use of mrna in vaccine development, availability of specialized quality control reagents.

The messenger ribonucleic acid quality monitoring market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to expansion of therapeutic mrna pipelines, increasing regulatory scrutiny of mrna products, growing investment in biopharmaceutical manufacturing, rising adoption of real-time quality analytics, expansion of contract research and manufacturing services. Major trends in the forecast period include increasing adoption of standardized mrna quality control protocols, rising use of advanced analytical instrumentation, growing integration of automated quality monitoring systems, expansion of regulatory compliance testing, enhanced focus on mrna stability and integrity.

The rising demand for personalized medicines is anticipated to drive the growth of the messenger ribonucleic acid (mRNA) quality monitoring market in the coming years. Personalized medicines are medical treatments designed to match an individual’s genetic profile, lifestyle, and environment to deliver the most effective therapy for that specific patient. The growing need for personalized medicines is fueled by the increasing prevalence of chronic and rare diseases, which require targeted, patient-specific therapies for improved treatment outcomes. Messenger ribonucleic acid quality monitoring ensures the precision, stability, and effectiveness of mRNA-based therapies, directly facilitating the development of safe and effective personalized medicines. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, showing a significant increase from the six approvals recorded in 2022. Consequently, the rising demand for personalized medicines is supporting the expansion of the messenger ribonucleic acid quality monitoring market.

Major companies operating in messenger ribonucleic acid (mRNA) quality monitoring are concentrating on developing innovative solutions, such as benchtop instruments, for rapid and precise evaluation of mRNA quality attributes. A benchtop instrument is a compact laboratory device designed to carry out specialized analyses or experiments on a laboratory bench, providing convenience, speed, and accessibility without the need for large-scale equipment. For example, in June 2024, InDevR Inc., a US-based biotechnology and analytical instrumentation company, introduced 5’CapQ, a rapid benchtop assay for evaluating critical quality attributes (CQAs) of mRNA-based vaccines. The assay assesses both the integrity and 5’ capping efficiency of mRNA molecules in under two hours, integrating these essential quality metrics into a single streamlined test. It functions by selectively capturing mRNA molecules with a 5’ cap and fluorescently labeling the poly(A) tail, ensuring that only fully intact, capped mRNA, which is crucial for stability and protein translation, is measured. By offering fast, quantitative, and user-friendly analysis, 5’CapQ helps remove testing bottlenecks in mRNA vaccine development without the need for specialized expertise or lengthy processing times.

In September 2024, Agilent Technologies Inc., a US-based technology and life sciences company, acquired BIOVECTRA Inc. for an undisclosed amount. Through this acquisition, Agilent intends to expand its biopharma services presence by incorporating contract development and manufacturing capabilities for biologics and advanced therapies. Biovectra Inc. is a Canada-based company that offers messenger ribonucleic acid (mRNA) quality monitoring.

Major companies operating in the messenger ribonucleic acid quality monitoring market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Lonza Group AG, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Intertek Group plc, Sartorius AG, Revvity Inc., Bio-Rad Laboratories Inc., WuXi Biologics (Cayman) Inc., QIAGEN N.V., Bio-Techne Corporation, Fujifilm Diosynth Biotechnologies, GenScript Biotech Corporation, Promega Corporation, Takara Bio Inc., Oxford Nanopore Technologies Ltd., Creative Biolabs Inc., Creative Diagnostics, Jena Bioscience GmbH.

North America was the largest region in the messenger ribonucleic acid quality monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid quality monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the messenger ribonucleic acid quality monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the messenger ribonucleic acid quality monitoring market by increasing costs of imported analytical instruments, reagents, consumables, laboratory software, and precision components. North America and Europe are most affected due to dependence on imported high-end laboratory equipment, while Asia-Pacific faces pricing pressure on export-oriented manufacturing. These tariffs are increasing operational costs for research and production facilities. However, they are also encouraging domestic instrument production, regional reagent manufacturing, and development of localized analytical service capabilities.

The messenger ribonucleic acid quality monitoring market research report is one of a series of new reports that provides messenger ribonucleic acid quality monitoring market statistics, including messenger ribonucleic acid quality monitoring industry global market size, regional shares, competitors with a messenger ribonucleic acid quality monitoring market share, detailed messenger ribonucleic acid quality monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid quality monitoring industry. This messenger ribonucleic acid quality monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) quality monitoring involves the systematic evaluation of the integrity, purity, and stability of mRNA molecules used in research, diagnostics, or therapeutics. This process ensures that the mRNA remains free from degradation, contaminants, or structural defects, which is essential for obtaining reliable experimental results and ensuring the safety and effectiveness of mRNA-based therapies.

The main types of messenger ribonucleic acid (mRNA) quality monitoring include analytical instruments, reagents and consumables, and software and services. Analytical instruments are specialized laboratory tools designed to evaluate and maintain the integrity, purity, and critical quality attributes of mRNA molecules throughout research, development, and production processes. The technologies employed include liquid chromatography-mass spectrometry (LC-MS), electrophoresis, enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR) techniques, and other related methods. These are applied in various areas such as vaccine development, therapeutic mRNA products, and gene editing, serving a range of end users including biopharmaceutical and biotechnology companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs) and analytical laboratories, as well as academic and research institutes or centers.

The messenger ribonucleic acid (mRNA) quality monitoring market consists of revenues earned by entities by providing services such as purity and contaminant testing, potency and functionality assays, stability and storage monitoring, analytical method development and validation, endotoxin testing, and capping efficiency analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The messenger ribonucleic acid (mRNA) quality monitoring market also includes sales of quantification kits, reference materials, detection devices, microfluidic platforms, and analytical software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.